About Anygen
Anygen is a company based in Gwangju (South Korea) founded in 2000 was acquired by HLB in March 2025. The company has 83 employees as of December 31, 2024.
- Headquarter Gwangju, South Korea
- Employees 83 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Hlb Pep Co. Ltd.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Anygen
Anygen is a publicly listed company on the KRX with ticker symbol 196300 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Anygen
Investors in Anygen
Anygen has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HLB and Solidus Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Marine composite materials are manufactured for industry applications.
|
Locked | Locked | Locked |
Investor details for Anygen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Anygen
Investment portfolio details for Anygen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Anygen
Detailed financials for Anygen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anygen Comparisons
Peer comparison for Anygen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Anygen
Detailed competitors of Anygen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anygen
Complete news archive for Anygen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anygen
Anygen was founded in 2000 and raised its 1st funding round 14 years after it was founded.
Anygen is headquartered in Gwangju, South Korea.
Jae Kim is the current CEO of Anygen.
As of Dec 31, 2024, the latest employee count at Anygen is 83.
Annual revenue of Anygen is $4.22M as on Dec 31, 2024.
Founded in 2000 and based in Gwangju, South Korea, operations center on the biotech sector with GMP and non-GMP production of custom, generic, and catalog peptides. Services are delivered via the Nano-Bio Research center. Three drug candidates are under development in the GIST unit: an anti-cancer agent targeting head and neck cancers, a peptide-based treatment for neuropathic pain, and an oral delivery platform. Licensing is anticipated after preclinical trials.
Yes, Anygen is publicly traded on KRX under the ticker symbol 196300.
Anygen has 2 investors. Key investors include HLB, and Solidus Investment.
The ticker symbol of Anygen is 196300 on KRX.